/	JIPE 40
N. S.	JUL 2 6 2004 E
¥	Anal re the A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The re the Application of:) Group Art Unit:
Wonderling, Ramani S.) Examiner:
Boroughs, Karen L.) INFORMATION DISCLOSURE
Serial No.: 10/821,670) <u>INFORMATION DISCLOSURE</u>) <u>STATEMENT</u>
Filed: April 9, 2004) CERTIFICATE OF MAILING
Atty. File No.: IM-5-1) I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS.
For: "CANINE AND FELINE PROTEINS,	P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450, ON THIS DAY OF JULY 2004
NUCLEIC ACID MOLECULES AND) HESKA CORPORATION
USES THEREOF") / / / / / /

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to Applicants' duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicants hereby provide the enclosed Form PTO-1449. The present application, Serial No. 10/821,670, relies upon the previously filed application, Serial No. 09/917,265, filed July 27, 2001, for an earlier filing date. Therefore, in accordance with 37 CFR § 1.98(d), copies of all documents listed on attached Form PTO-1449 that were previously submitted or cited by the U.S. Patent and Trademark Office in Application Serial No. 09/917,265 (documents A1-A8, B1-B4 and C1-C32) are not herein provided.

Respectfully submitted,

Dated: July <u>21</u>, 2004

Richard J. Stern Ph.D. Registration No. 50,668 Heska Corporation 1613 Prospect Parkway

Fort Collins, Colorado 80525 Telephone: (970) 493-7272

Facsimile: (970) 491-9976

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Page 1 of 2

ATTY. DOCKET NO. IM-5-1

SERIAL NO. 10/821,670

APPLICANT Ramani S. Wonderling; Karen L. Boroughs

FILING DATE April 9, 2004

GROUP

277	U.S. PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	ISSUE DATE	PATENTEE	CLS	SUB-CLS	FILE DATE
	A1	5,858,778	January 12, 1999	Alnemri, et al.			
	A2	5,912,324	June 15, 1999	Okamura, et al.			
	А3	5,914,253	June 22, 1999	Okamura, et al.			
	A4	5,919,790	July 6, 1999	Allen, et al.			
	A5	5,942,224	August 24, 1999	Miwa, et al.			
	A6	5,945,310	August 31, 1999	Young, et al.			
	A7	5,985,863	November 16, 1999	Su, et al.			
	A8	6,013,268	January 11, 2000	Reed			

	FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATIONS						
EXAM. INITIAL		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLS	SUB-CLS	TRANS
	B1	WO 98/51327	19 November 1998	PCT			
	B2	WO 99/07851	18 February 1999	PCT			
	В3	WO 99/50425	07 October 1999	PCT			
	B4	WO 00/12555	09 March 2000	PCT			

		OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)
	CT	Argyle, et al., Accession No. Y11133, 07-Jul-1999
	C2	Argyle, et al., Immunogenetics, 1999 June, Vol. 49, No. 6, pages 541-543
	СЗ	Belke-Louis, G.F., Accession No U49085, 13-Mar-1996
	C4	Belke-Louis, G.F., Accession No U49100, 13-Mar-1996
	C5	Carr, et al., <i>Journal of Virology</i> , Oct. 1997, Vol. 71, No. 10, pages 7799-7803
	C6	Cerretti, et al., Accession No. M87507, 18-May-1995
	C 7	Culhane, et al., Accession No. AJ222813, 11-Aug-1998
	C8	Johnson, et al., Accession No. AF031351, 03-Nov-1998
	C9	Keane, et al., Accession U14647, 27-Jan-1996
EXAMINER		DATE CONSIDERED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 2 of 2

ATTY. DOCKET NO. IM-5-1

SERIAL NO. 10/821,670

APPLICANT Ramani S. Wonderling; Karen L. Boroughs

FILING DATE April 9, 2004

GROUP

	C10	OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)
		Lee, et al., Human Gene Therapy, March 1, 1998, Vol. 9, pages 457-465
	C11	Lieschke, et al., Nature Biotechnology, Vol. 15, January 1997, pages 35-40
	C12	Lode, et al., Proc. Natl. Acad. Sci. USA, Vol. 95, March 1998, pages 2475-2480
	C13	Molineaux, et al., Accession No. L28095, 27-July-1994
	C14	Mortola, et al., <i>J Vet Med Sci</i> , 1998, Vol. 60, No. 11, pages 1181-1185
	C15	Nicolson, L., et al., Accession No. Y11131, 07-Jul-1999
	C16	Okamura, H., Accession No. D49949, 10-Feb-1999
	C17	Okano, F., Accession No. E15017, 28-Jul-1999
	C18	Okano, F., Accession NO. E15018, 28-Jul-1999
	C19	Okano, et al., Journal of Interferon and Cytokine Research, 1997, Vol. 17, pages 713-718
	C20	Okano, et al., Journal of Interferon and Cytokine Research, 1999, Vol. 19, pages 27-32
	C21	Osaki, et al., The Journal of Immunology, 1998, Vol. 160, pages 1742-1749
	C22	Penha-Goncalves, et al., Accession No. Y11132, 07-Jul-1999
	C23	Pirhonen, et al., The Journal of Immunology, 1999, Vol. 162, pages 7322-7329
	C24	Rogerson, et al., <i>Ann N Y Acad Sci</i> , 1996 Oct. 31, Vol. 795, pages 354-356
	C25	Sareneva et al., The Journal of Immunology, 1998, Vol. 160, pages 6032-6038
	C26	Schijns, V.E.C.J., Accession No. Y07761, 13-May-1997
	C27	Schijns, et al., Accession No. Y07762, 13-May-1997
	C28	Taylor, et al., Accession No. AF135967, 12-Jul-2000
	C29	Ushio, S., Accession No. D49950, 10-Feb-1999
-	C30	Wardlow, et al., Accession No. AF090119, 02-Aug-1999
Ì	C31	Yoshimoto, et al., The Journal of Immunology, 1998, Vol. 161, pages 3400-3407
	C32	Yoshimoto, et al., Proc. Natl. Acad. Sci. USA, April 1997, Vol. 94, pages 3948-3953
	C33	Foss, et al., 1999, <i>Scand. J. Immunol.</i> , Vol. 50, pages 596-604
	C34	Peng, et al., 1999, The Journal of Immunology, Vol. 163, pages 250-258
EXAMINER		DATE CONSIDERED